Amgen Fraud Suit to Proceed as Class-Action
The U.S. Supreme Court shot down an effort by Epogen-maker Amgen to disqualify a securities fraud case as a class-action suit, sending the claims back to a lower court.
Tags:
Amgen Fraud Suit to Proceed as Class-Action,
Amgen Latest News